CNAT - After Third Consecutive NASH Trial Failure Conatus' Future Appears Bleak

Last week, on March 21, Conatus (NASDAQ: CNAT) announced that its lead drug candidate, emricasan, had failed to reach its primary endpoint in a Phase 2 clinical trial evaluating the drug's ability to treat NASH fibrosis. On March 22, share price opened at $1.35 (a 53.6% drop from the March 21 closing price of $2.91), signaling that many investors appear to have lost faith in the company. Now, it's do or die for Conatus - if emricasan fails its fourth and final Phase 2 NASH clinical trial, the company will almost certainly be forced

Read more ...